877 results on '"Kvien, Tore K"'
Search Results
2. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration
3. Associations between pain sensitization and measures of physical function in people with hand osteoarthritis: Results from the Nor-Hand study
4. Comorbidities in people with hand OA and their associations with pain severity and sensitization: Data from the longitudinal Nor-Hand study
5. Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models
6. Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients
7. The associations of psychological symptoms and cognitive patterns with pain and pain sensitization in people with hand osteoarthritis
8. Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data
9. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
10. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
11. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis
12. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
13. Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
14. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries.
15. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
16. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept:Results from the international TOCERRA and PANABA observational collaborative studies
17. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
18. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials
19. Generic Tofacitinib—A More Affordable JAK Inhibitor
20. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
21. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study
22. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
23. Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity.
24. Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study.
25. Course and predictors of work productivity in gout—results from the NOR-Gout longitudinal 2-year treat-to-target study
26. Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration
27. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries
28. Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
29. Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis
30. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
31. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis
32. Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
33. Immunogenicity and Safety of Standard and Third‐Dose SARS – CoV ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
34. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries
35. Controversies in rheumatology: maintenance therapy with low-dose glucocorticoids in rheumatoid arthritis
36. Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
37. 231: PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; RESULTS FROM A 52-WEEK MULTICENTRE RANDOMISED TRIAL OF 450 PATIENTS
38. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
39. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
40. Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout:results from the NOR-Gout study
41. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
42. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis:Long-Term Results of Two Phase III Randomized Controlled Trials
43. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients
44. Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact
45. Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
46. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study
47. Associations of Body Mass Index With Pain and the Mediating Role of Inflammatory Biomarkers in People With Hand Osteoarthritis
48. Additional file 1 of Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data
49. Additional file 1 of The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
50. Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.